Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,709 shares of the biopharmaceutical company’s stock after selling 388 shares during the period. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $1,077,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Capital World Investors lifted its position in shares of Gilead Sciences by 2.0% during the 4th quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock valued at $6,753,350,000 after acquiring an additional 1,642,736 shares during the period. Capital Research Global Investors lifted its position in shares of Gilead Sciences by 3.0% during the 4th quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after acquiring an additional 1,743,418 shares during the period. Wellington Management Group LLP lifted its position in shares of Gilead Sciences by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after acquiring an additional 2,350,550 shares during the period. Morgan Stanley lifted its position in shares of Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after acquiring an additional 158,794 shares during the period. Finally, Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $1,301,624,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 1.7 %

GILD stock opened at $63.15 on Thursday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a 50 day moving average price of $65.69 and a two-hundred day moving average price of $73.06. The stock has a market capitalization of $78.68 billion, a P/E ratio of 175.42, a PEG ratio of 1.27 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the company earned $1.37 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.88%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Analyst Ratings Changes

GILD has been the subject of a number of research reports. Barclays reduced their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Maxim Group dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research note on Wednesday, April 24th. Mizuho dropped their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $83.69.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.